Singapore markets closed

AEON Biopharma, Inc. (AEON)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
0.9776+0.0170 (+1.78%)
At close: 04:00PM EDT
0.9700 -0.00 (-0.40%)
After hours: 04:06PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.9605
Open1.0100
Bid0.9606 x 900
Ask1.0400 x 800
Day's range0.9700 - 1.0200
52-week range0.9180 - 17.1700
Volume8,453
Avg. volume85,370
Market cap38.246M
Beta (5Y monthly)0.40
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

    Current cash and cash equivalents expected to be sufficient to support corporate operations into Q4 2024; evaluating options to fund future advancement of late-stage clinical pipelineIRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced a strategic reprioritization an

  • GlobeNewswire

    AEON Biopharma Reports First Quarter 2024 Financial Results

    – Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints – – Evaluating next-steps across the Company’s late-stage clinical pipeline for ABP-450 that targets multiple indications – IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatmen

  • GlobeNewswire

    AEON Biopharma Provides Update on Development Pipeline

    Includes two late-stage clinical programs and two early-stage clinical programsIRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications. “In addition to our ear